Harmony Biosciences Holdings (HRMY) Net Income (2019 - 2026)
Harmony Biosciences Holdings (HRMY) posted Net Income of $32.5 million for Q1 2026, down 50.22% sequentially from $65.3 million in Q4 2025, and down 28.69% YoY from $45.6 million in Q1 2025.
Harmony Biosciences Holdings (HRMY) Net Income (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Net Income for 8 years, with the latest figure at $32.5 million in Q1 2026.
- Quarterly Net Income fell 28.69% year-over-year to $32.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $188.4 million (up 23.36% YoY) and the FY2025 annual result came in at $201.5 million, up 38.47% from the prior year.
- Net Income fell to $32.5 million in Q1 2026 per HRMY's latest filing, from $65.3 million in the prior quarter.
- Over five years, Net Income peaked at $87.9 million in Q3 2022 and troughed at $11.6 million in Q2 2024.
- A 5-year average of $40.6 million and a median of $38.5 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2024: Net Income jumped 1014.17% in 2022, then tumbled 66.21% in 2024.
- Over 5 years, Net Income stood at $48.5 million in 2022, then sank by 45.15% to $26.6 million in 2023, then surged by 85.95% to $49.5 million in 2024, then soared by 31.91% to $65.3 million in 2025, then tumbled by 50.22% to $32.5 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered $32.5 million, $65.3 million, and $50.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 73.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.68 Mn |
| Mar 31, 2026 | 32.49 Mn |
| Dec 31, 2025 | 65.26 Mn |
| Sep 30, 2025 | 50.87 Mn |
| Jun 30, 2025 | 39.78 Mn |
| Mar 31, 2025 | 45.56 Mn |
| Dec 31, 2024 | 49.48 Mn |
| Sep 30, 2024 | 46.09 Mn |
| Jun 30, 2024 | 11.59 Mn |
| Mar 31, 2024 | 38.33 Mn |
| Dec 31, 2023 | 26.61 Mn |
| Sep 30, 2023 | 38.46 Mn |
| Jun 30, 2023 | 34.30 Mn |
| Mar 31, 2023 | 29.49 Mn |
| Dec 31, 2022 | 48.51 Mn |
| Sep 30, 2022 | 87.94 Mn |
| Jun 30, 2022 | 23.53 Mn |
| Mar 31, 2022 | 21.49 Mn |
| Dec 31, 2021 | 22.71 Mn |
| Sep 30, 2021 | -9.62 Mn |